This page is updated frequently with new Leukemia-related patent applications.
|Antagonists of slc38a9 and their use in therapy|
The present invention relates to an antagonist or modulator of slc38a9 for use in treating a disease associated with mtorc1 activation, like a proliferative disease (e.g. A cancerous disease or benign proliferative disease), a metabolic disorder, a disorder of the immune system, a disorder causing premature aging, an ophthalmic disorder or a neurological disorder.
Cemm - Forschungzentrum Fuer Molekulare Medizin Gmbh
|Combination therapy with double negative t-cells|
There is provided herein methods of treating leukemia or lymphoma in a subject in need thereof, with double negative t cells (dnts) in combination with interferon-γ.. .
University Health Network
|Combination therapy for the treatment of cancer|
Described are methods and compositions for treating cancer that include a dopamine receptor (dr) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a dna synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel.
|Humanized anti-hla-dr antibodies|
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
|Treatment of cancer with dihydropyrazino-pyrazines|
Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a dihydropyrazino-pyrazine compound to a patient having chronic lymphocytic leukemia.. .
Signal Pharmaceuticals, Llc
|Bosutinib forms and preparation methods thereof|
The present subject matter relates to solvates and the amorphous form of bosutinib; the solvates namely being a propylene glycol solvate and an acetonitrile solvate. Also provided are processes for preparing the propylene glycol solvate, the amorphous form and the crystalline acetonitrile solvate of bosutinib; as well as compositions comprising said forms.
|Method for treating cancer|
A method for the treatment of cancer by administering a therapeutically effective amount of a cyclin-dependent kinase (cdk) inhibitor with a therapeutically effective amount of a b cell chronic lymphocytic leukemia/lymphoma 2 inhibitor (“b cell cll/lymphoma 2”, or “bcl-2”). Administration of the cdk inhibitor and bcl-2 inhibitor can be simultaneous, successive or separate..
Merck Sharp & Dohme Corp.
|High-sensitivity sequencing to detect btk inhibitor resistance|
A method for predicting resistance to btk inhibitors in patients with chronic lymphocytic leukemia (cll) enhances the sensitivity of sanger sequencing and ngs by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free dna..
Neogenomics Laboratories, Inc.
|Chimeric protein toxins for expression by therapeutic bacteria|
Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic.
|Anti-vista antibodies and fragments|
The present invention relates to novel antibodies and fragments that bind to a v-domain ig suppressor of t cell activation (vista), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas..
Janssen Pharmaceutica Nv
The invention relates to a compound of formula (i) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (i) are useful as therapeutic agent for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, type i diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, inflammatory bowel diseases, crohn's disease, alzheimer's disease, leukemia, osteoarthritis, control of pruritus, chronic respiratory disease or keratoconjunctivitis in mammals..
Novartis Tiergesundheit Ag
Method for slowing the aging process
A method of slowing the aging process by extracorporeally treating a patient's blood is described. Certain antigens are known to be associated with aging.
Marv Enterprises, Llc
Method for treating infectious diseases using emissive energy
The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc
Inhibitor of inflammatory conditions
The invention relates to boswellia frereana and particularly an extract of same for treating a range of inflammatory disorder or conditions selected from the group comprising: inflammatory bowel disease (ibd), all forms of muscular dystrophy especially duchenne muscular dystrophy, sepsis, sepsis syndrome, osteoporosis, ischemic injury, graft vs. Host disease, reperfusion injury, asthma, diabetes, cancer, myelogenous and other leukemias, psoriasis and cachexia, alzheimer's disease, demyelinating neurological disorders including multiple sclerosis, acetylcholinesterase mediated disorders, retinal disorders, neurological, retinal, and muscular disorders..
Compton Developments Ltd.
Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
A method of treating acute myeloid leukemia, acute lymphoblastic leukemia, high risk myelodysplastic syndrome, and/or hr-mds/aml in a mammal by administering a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the formula (1) wherein r1 is alkyl having a carbon number of 1-4, r2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, r3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —nr5-(ch2)m r6 wherein r5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and r6 is phenyl or pyridyl optionally substituted by a halogen atom.. .
Method for predicting prognosis of acute myeloid leukemia relapse
The present invention relates to a method for predicting the prognosis of acute myeloid leukemia relapse. According to the present invention, the prognosis of acute myeloid leukemia relapse can be predicted by analyzing changes in a bone marrow microenvironment during the early diagnosis of leukemia..
The Catholic University Of Korea Industry-academic Cooperation Foundation
New biomarker for aml
The present invention relates to an in vitro method for predicting the survival time of a subject suffering from acute myeloid leukemia (aml) comprising determining, in a biological sample from the subject, the epigenetic profile of the h3k27.. .
UniversitÉ D'aix Marseille
Sirna in tandem expression and uses thereof in treating chronic lymphocytic leukemia
Provided is an sirna in tandem expression and uses thereof in treating chronic lymphocytic leukemia, and particularly, provided are a method of a tandem expression for sirna of btk, and an sirna in tandem expression and uses thereof in treating chronic lymphocytic leukemia.. .
Jiangsu Micromedmark Biotech Co., Ltd.
Superagonists, partial agonists and antagonists of interleukin-2
Novel human interleukin-2 (il-2) muteins or variants thereof are provided. In particular, provided are il-2 muteins that have an increased binding capacity for il-2rp receptor and a decreased binding capacity for il-2rγc receptor, as compared to wild-type il-2.
United States Department Of Health And Human Service, Office Of Technology Transfer, National
Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation
A composition for human and animal use as a therapy for the treatment of tumors, acquired immunodeficiency syndrome and leukemias is described. The composition, for human and animal use as an antitumor agent has a strain of bacteria lactobacillus reuteri lre 03 dsm 23879 which is able to strongly stimulate the production of pro-inflammatory cytokines (th1) interferon inf-gamma, the cytokines exhibiting a marked antitumor activity, and/or a strain of bacteria lactobacillus salivarius ls06 dsm 26037 which is able to strongly stimulate the production of dendritic cells, the dendritic cells also exhibiting a marked antitumor activity..
Methods for treating t-cell acute lymphoblastic leukemia
The present invention is directed to methods of treating t-all that involve administering an inhibitor of jumonji d3 (jmjd3) demethylase. Another embodiment of the invention relates to methods inhibiting t-all cell proliferation and/or survival that involves administering an inhibitor of jumonji d3 (jmjd3) demethylase to a population of t-all cells..
New York University
Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
A method of identifying a subject having chronic lymphocytic leukemia (cll) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having cll; administering 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione (compound a) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.. .
Genetic modification of rats
Compositions and methods are provided for making rat pluripotent and totipotent cells, including rat embryonic stem (es) cells. Compositions and methods for improving efficiency or frequency of germline transmission of genetic modifications in rats are provided.
Regeneron Pharmaceuticals, Inc.
Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
The present invention provides an inhibitor against cd112 (nectin-2, pvrl2), cd155 (pvr), galectin-9, tim-3 and/or tigit for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (aml). Moreover, the present invention provides a pharmaceutical composition comprising an inhibitor against cd112 (nectin-2, pvrl2), cd155 (pvr), galectin-9, tim-3 and/or tigit and a car t cell.
Amgen Research (munich) Gmbh
Drug delivery conjugates for treating resistant cancer and for use in combination therapy
Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases.
Uses of hypoxia-inducible factor inhibitors
The present invention relates to treating a hematologic cancer using a hypoxia-inducible factor (hif inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the hif inhibitor.
Methods and reagents for the diagnosis and treatment of acute leukemia
The present invention is directed to methods of treating t-all that involves administering a therapeutic agent that inhibits a notch-1 regulated non-coding rna (lncrna). Another embodiment of the invention relates to methods and kits for diagnosing t-all that involve detecting and quantifying the expression level of notch1-regulated lncrnas is a biological sample from a subject..
New York University